Zileuton

Drug Profile

Zileuton

Alternative Names: A 64077; Abbott 64077; ABT 077; CRTX 073; CTI-02; Zileuton CR; Zyflo; ZYFLO CR; ZYFLO Filmtab

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Abbott Laboratories
  • Developer Chiesi USA; National Heart, Lung and Blood Institute; University of Minnesota
  • Class Antiasthmatics; Small molecules; Urea compounds
  • Mechanism of Action 5-lipoxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma
  • Discontinued Acne; Acute asthma; Allergic rhinitis; Atherosclerosis; Atopic dermatitis; Cancer; Chronic obstructive pulmonary disease; Nasal polyps; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 28 Apr 2014 Cornerstone Therapeutics is now called Chiesi USA
  • 04 Feb 2014 Cornerstone Therapeutics has been acquired by Chiesi Farmaceutici
  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top